Trade Abbott Laboratories - ABT CFD
Add to favourite- Summary
- Historical Data
Spread | 0.14 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024846% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002624% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 114.56 |
Open | 114.66 |
1-Year Change | 18.4% |
Day's Range | 114.66 - 114.99 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 8, 2024 | 114.56 | 1.20 | 1.06% | 113.36 | 115.18 | 113.36 |
Oct 7, 2024 | 113.28 | 1.19 | 1.06% | 112.09 | 113.53 | 111.75 |
Oct 4, 2024 | 112.56 | 0.21 | 0.19% | 112.35 | 112.70 | 111.61 |
Oct 3, 2024 | 112.15 | -0.26 | -0.23% | 112.41 | 113.44 | 111.70 |
Oct 2, 2024 | 113.57 | 1.13 | 1.00% | 112.44 | 113.72 | 111.97 |
Oct 1, 2024 | 113.51 | 0.03 | 0.03% | 113.48 | 114.08 | 112.74 |
Sep 30, 2024 | 113.94 | 1.71 | 1.52% | 112.23 | 114.03 | 112.06 |
Sep 27, 2024 | 112.35 | -0.48 | -0.43% | 112.83 | 113.30 | 112.24 |
Sep 26, 2024 | 112.64 | 0.63 | 0.56% | 112.01 | 112.87 | 112.01 |
Sep 25, 2024 | 112.47 | -0.49 | -0.43% | 112.96 | 114.00 | 111.80 |
Sep 24, 2024 | 113.33 | -0.53 | -0.47% | 113.86 | 114.35 | 113.11 |
Sep 23, 2024 | 114.72 | 1.36 | 1.20% | 113.36 | 114.83 | 112.89 |
Sep 20, 2024 | 113.60 | 0.54 | 0.48% | 113.06 | 114.09 | 112.95 |
Sep 19, 2024 | 114.07 | -0.91 | -0.79% | 114.98 | 115.52 | 113.18 |
Sep 18, 2024 | 114.79 | -2.29 | -1.96% | 117.08 | 117.27 | 113.88 |
Sep 17, 2024 | 118.06 | 1.01 | 0.86% | 117.05 | 118.44 | 116.71 |
Sep 16, 2024 | 117.56 | 1.12 | 0.96% | 116.44 | 117.62 | 116.35 |
Sep 13, 2024 | 116.33 | 0.93 | 0.81% | 115.40 | 116.97 | 115.35 |
Sep 12, 2024 | 116.71 | 0.78 | 0.67% | 115.93 | 117.24 | 115.45 |
Sep 11, 2024 | 116.50 | 0.19 | 0.16% | 116.31 | 116.65 | 114.63 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Abbott Company profile
What is Abbott Laboratories?
Abbott Laboratories is a US healthcare company that employs around 99,000 people and delivers its services in over 150 countries worldwide. Abbott produces and distributes a range of products under such popular brands as PediaSure, Glucerna, Similac, Absorb and others. Its mission statement is: “To improve lives by providing cost-effective health care products and services.”
The company focuses on the following healthcare segments: Nutrition, Vascular Care, Diabetes Care, Vision, Pharmaceuticals and Diagnostics. It advocates for innovation in medicine and works to improve vision correction, take heart health treatments to the next level and introduce innovative methods of diabetes management.
Abbott has also pioneered new ways to screen, diagnose and monitor a wide range of health conditions with greater speed and accuracy. In pharmaceuticals, the company has revolutionised packaging and delivery to meet regional needs and offer access to medicines in areas that once lacked them.
Who are the key people at Abbott Laboratories?
Miles D. White is Chairman and Chief Executive Officer of Abbott. He has held both roles since 1999, and first joined the company back in 1984. Another key figure at Abbott Laboratories is Brian Blaser, Executive Vice President, Diagnostics Products. He leads Abbott's diagnostics, molecular and point-of-care businesses. Robert Ford is Executive Vice President, Medical Devices.
What is the modern history of Abbott Laboratories?
Abbott was incorporated in 1894, and its initial public offering took place in 1929. Among a number of landmark developments in the second half of the 20th century was the acquisition of M&R Dietetics in 1964, which made the company a leader in nutrition. Abbott’s modern diagnostics business took off in the early 1970s, and in 1985 the FDA approved the firm’s test to identify HIV in blood. In 1998 Abbott introduced Glucerna – a range of snack bars and shakes for diabetics. The first decade of the 21st century saw FDA approval of antibody drug Humira, which became the world’s leading pharmaceutical product.
What are the latest developments at Abbott Laboratories?
In January 2017 Abbott completed the acquisition of St Jude Medical – a development which put the company in a leading position in the medical devices sector. Abbott now holds the No.1 or No.2 positions in nearly every segment of the $30 billion cardiovascular market. In 2017 Abbott also recorded 40 per cent growth in its neuromodulation business, attaining the No.1 spot in spinal cord neurostimulation.
In February 2018, Abbott announced a licensing deal with mid-tech firm Surmodics Inc that could be worth up to $92 million. Under the agreement, Surmodics will exclusively license its SurVeil drug-coated balloon device to Abbott. Surmodics is testing it as a treatment for peripheral artery disease.
Since the start of 2015, the Abbott share price has ranged from a low of around $37 in February 2016 to over $60 in January 2018. The company’s market capitalisation on 2 March 2018 was $103.5 billion. Our ABT chart tracks Abbott’s recent share price movements.
Where does Abbott Laboratories operate?
Abbott is headquartered in Chicago, Illinois. It has a truly global presence, with operations across the Americas, Europe and Asia Pacific – including China, India, Japan, Australia and New Zealand.
Where is Abbott Laboratories traded?
Abbott Laboratories is listed on the New York Stock Exchange. As of 2017, the shares were mainly held by institutional investors such as BlackRock, State Street Corporation and The Vanguard Group. Check out Capital.com for the latest ABT chart.
Industry: | Medical Equipment, Supplies & Distribution (NEC) |
100 Abbott Park Rd
ABBOTT PARK
ILLINOIS 60064-3500
US
News
US Core CPI tipped to remain unchanged in September
US inflation expectations are steady, with core CPI projected to remain at 3.2% for September while headline inflation moderates to its lowest level since February 2021. Despite the US Federal Reserve delivering a 50 basis point interest rate cut in September, stronger-than-expected job market data has raised concerns about sustained economic demand and inflation pressures.
07:10, 9 October 2024RBNZ expected to deliver “jumbo” rate cut
The Reserve Bank of New Zealand is set to cut interest rates during its upcoming meeting, with expectations of either a 25 or 50 basis point reduction. This move follows a 25 basis point cut in August as the RBNZ responded to the country’s recessionary conditions and inflation concerns.
08:48, 8 October 2024September Non-Farm Payrolls eases fears of US economic slowdown
Markets are reacting with a US Dollar surge and a potential trend reversal, highlighting the impact of robust economic activity outside of monetary policy influences.
07:44, 8 October 2024Gold's recent story
Last week, we explored the key price drivers of gold, and how they impacted the price of the precious metal this year and last. Now, we’ll bring these factors to life in a chart, showing you ten instances the gold price responded to critical fundamental events, including central bank policies, global economic data, and geopolitical events.
15:36, 7 October 2024September US Non-Farm Payrolls Preview
Kyle Rodda, Senior Market Analyst at Capital.com, previews the US Non-Farm Payrolls report for September. The article discusses market expectations of a stable labor market with 150,000 new jobs, an unchanged unemployment rate of 4.2%, and steady annual wage growth at 3.8%. It also highlights potential rate cuts by the Federal Reserve, revisions to past payroll data, and the reaction of various markets such as the US Dollar, S&P 500, and gold.
07:59, 2 October 2024Market of the Month - Gold, an overview
In 2024, gold has been on an upward trajectory, hitting high after high as global markets face ongoing challenges. This precious metal, long seen as a safe haven, has been proving its worth, drawing attention from traders around the world as its bullish surge continues.
06:00, 30 September 2024RBA Preview: Rates to remain unchanged with inflation-fighting still the focus
RBA Governor Michelle Bullock emphasizes inflation challenges for Australia's economy, citing supply shocks and demand-supply imbalances. Discover insights on CPI trends, interest rates, and the central bank's strategy for managing price pressures in 2024.
12:27, 20 September 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com